The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sivkova S.N.

Detskaia gorodskaia bol'nitsa #8, Kazan';
Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. N.I. Pirogova, Moskva

Milovanova O.A.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia;
Tushinskaia detskaia gorodskaia bol'nitsa, Moskva

Zaĭkova F.M.

Optimization of treatment focal forms of epilepsy in young children

Authors:

Sivkova S.N., Milovanova O.A., Zaĭkova F.M.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(9): 43‑47

Read: 1446 times

Download PDF (RU)
Contact the author
Table of contents

OPTIMIZATION OF TREATMENT FOCAL FORMS OF EPILEPSY IN YOUNG CHILDREN
OPTIMIZATION OF TREATMENT FOCAL FORMS OF EPILEPSY IN YOUNG CHILDREN

To cite this article:

Sivkova SN, Milovanova OA, Zaĭkova FM. Optimization of treatment focal forms of epilepsy in young children. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(9):43‑47. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Auto­nomic cardiovascular diso­rders in patients with epileptic and psychogenic non-epileptic seizures: a pilot study. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):13-20
The pote­ntial of cortical electrical stimulation for the study of auto­nomic dysfunction in patients with epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):25-34
The role of neuroinflammation in the deve­lopment of seizure acti­vity and auto­nomic diso­rders in patients with epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):50-58
Epileptogenesis and risk factors of symptomatic epileptic seizures in patients with acute cere­brovascular acci­dents. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):26-31
The rela­tionship between the inte­rictal para­meters of cardiovascular auto­nomic regu­lation and the outcomes of surgical treatment of epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):50-59
Factors and features of the deve­lopment of epilepsy in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):18-27
Type 28 spinocerebellar ataxia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):61-64
Evolution of DEE-SWAS into photosensitive epilepsy in a patient with an ASH1L gene muta­tion. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):114-119
Epileptogenesis and functional labi­lity of the genome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):19-26
A personalized approach to the diagnosis of epilepsy in obese children. Labo­ratory Service. 2025;(1):5-12
Abstract:

A clinical trial included 30 children, aged from 24 to 46 months, stratified into two groups on the basis of clinical-instrumental data: 22 (73%) patients with symptomatic focal epilepsy and 8 (27%) patients with cryptogenic (possibly symptomatic) focal epilepsy. Topamax (topiramate) was used as mono- (8 children) and combined (22 children) therapy. Mean treatment dose was 5,9 mg/kg per day. Efficacy of treatment was evaluated by the changes in frequency of seizures. After 6 months, the positive result (completed stopping of seizures or their reduction by 50% and more) was seen in 19 (63,75%) patients. The effect was absent or was minimal in 9 (29,5%). In 2 (6,75%) cases the frequency of seizures increased. Adverse events were recorded in 11 (36%) patients, side-effects that led to the treatment discontinuation (vomiting, increasing of seizure frequency, enuresis) were found in 5 (16%) patients.

Keywords:

epilepsy
topiramate (topamax)
children of young age

Authors:

Sivkova S.N.

Detskaia gorodskaia bol'nitsa #8, Kazan';
Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. N.I. Pirogova, Moskva

Milovanova O.A.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia;
Tushinskaia detskaia gorodskaia bol'nitsa, Moskva

Zaĭkova F.M.

Close metadata

References:

  1. Voronkova K.V., Pylaeva O.A., Petrukhin A.S. Effektivnost' topiramata (topamaksa) u bol'nykh epilepsiei raznogo vozrasta. Zhurn nevrol i psikhiat 2006; 106: 6: 34-37.
  2. Gromov S.A., Kharitonov R.A., Mikhailov V.A. i dr. Topamaks v sisteme medikamentoznogo lecheniya epilepsii. Zhurn nevrol i psikhiat 2004; 3: 38-41.
  3. Guzeva V.P., Kovelenova M.V., Fomina M.Yu. Topamaks v lechenii rezistentnykh form epilepsii u vzroslykh i detei. Zhurn nevrol i psikhiat 2004; 12: 61-63.
  4. Dorofeeva M.Yu., Ermakov A.Yu., Belousova E.D. Effektivnost' topiramata (topamaksa) v lechenii rezistentnoi epilepsii u detei. Zhurn nevrol i psikhiat 2005; 11: 21-23.
  5. Zenkov L.R. Klinicheskaya epileptologiya (s elementami neirofiziologii). M: OOO "Meditsinskoe informatsionnoe agentstvo" 2002; 416.
  6. Zenkov L.R., Prityko A.G. Farmakorezistentnye epilepsii. M: Medpress-inform 2003; 207.
  7. Mukhin K.Yu., Glukhova L.Yu., Petrukhin A.S. i dr. Topamaks pri monoterapii epilepsii. Zhurn nevrol i psikhiat 2004; 8: 35-40.
  8. Nikanorova M.Yu., Ermakov A.Yu., Belousova E.D. Dostizheniya i problemy farmakoterapii epilepsii u detei. Zhurn Ros vestn perinatol i pediat 2002; 5: 23-27.
  9. Al Ajlouni S., Shorman A., Daoud A.S. The efficacy and side effects of topiramate on refractory epilepsy in infants and young children: a multi-center clinical trial. Seizure 2005; 14: 7: 459-463.
  10. Alarcon-Martinez H., Casas-Fernandez S., Escudero-Rodriguez N. et al. Nephrolithiasis and topiramate. Rev Neurol 2006; 42; 2: 91-94.
  11. Bentue-Ferrer D., Tribut O., Verdier M.C. et al. Therapeutic drug monitoring of topiramate. Therapie 2010; 65: 1: 17-22.
  12. Coppola G., Capovilla G., Montagnini A. et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Research 2002; 49: 1: 45-48.
  13. Costa C., Martella G., Picconi B. et al. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke 2006; 37: 5: 1319-1326.
  14. Glauser T.A., Clark P.O., McGee K. Long-term response to topiramate in patients with West syndrome. Epilepsia 2000; 41: Suppl 1: 91-94.
  15. Grosso S., Galimberti D., Farnetani M.A. Efficacy and safety of topiramate in infants according to epilepsy syndromes. Seizure 2005; 14: 3: 183-189.
  16. Grosso S., Franzoni E., Iannetti P. Efficacy and safety of topiramate in refractory epilepsy of childhood: long-term follow-up study. J Child Neurol 2005; 20: 11: 893-897.
  17. Herranz J.L. Topiramate: a broad spectrum antiepileptic administered to 224 patients with refractory epilepsies. Rev Neurol 2000; 31: 9: 822-828.
  18. Holland K.D., Wyllie P.E. Use of topiramate in localization-related epilepsy in children. J Child Neurol 2000; 15: Suppl1: 3-6.
  19. Hosain S.A., Merchant S., Solomon G.E. Topiramate for the treatment of infantile spasms. J Thild Neurol 2006; 21: 1: 17-19.
  20. Kaminska A. New antiepileptic drugs in childhood epilepsies: indications and limits. Epileptic Disord 2001; 3: 2: 37-46.
  21. Latini G., Verrotti A., Manco R. et al. Topiramate: its pharmacological properties and therapeutic efficacy in epilepsy. Mini Rev Med Chem 2008; 8: 1: 10-23.
  22. Levisohn P.M. Safety and tolerability of topiramate in children. J Child Xeurol 2000; 15: Suppl 1: 22-26.
  23. Martin P., Schreiner A., Rettig K. et al. Topiramate in patients with epilepsy and intellectual disability. Epilepsy Behav 2009; 14: 3: 496-502.
  24. Mikaeloff Y., de Saint-Martin A., Mancini J. et al. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res 2003; 53: 3: 225-232.
  25. Mikaeloff Y., Rey E., Soufflet C. et al. Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years. Epilepsia 2004; 45: 11: 1448-1452.
  26. Nieto-Barrera M., Candau R., Xieto-Jimenez M. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 2000; 9: 8: 590-594.
  27. Ormrod D., McClellan K. Topiramate: a review of its use in childhood epilepsy. Paediatr Drugs 2001; 3: 4: 293-319.
  28. Pellock J. Antiepileptic drugs trials: Xeonates and infants. Epilepsy Research 2006; 68: 1: 42-45.
  29. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; 61: 3: 246-255.
  30. Shechter T., Shorer Z., Kramer U. et al. Adverse reactions of Topiramate and Lamotriginojn children. Pharmacoepidemiol Drug Saf 2005; 14: 3: 187-192.
  31. Smyth M.D., Limbrick D.D.Jr., Ojemann J.G. et al. Outcome following surgery for temporal lobe epilepsy with hippocampal involvement in preadolescent children: emphasis on mesial temporal sclerosis. J Neurosurg 2007; 106: Supll 3: 205-210.
  32. Sommer B.R., Fenn H.H. Review of topiramate for the treatment of epilepsy in elderly patients. Clin Interv Aging 2010; 26: 5: 89-99.
  33. Spencer S., Huh L. Outcomes of epilepsy surgery in adults and children. Lancet Neurol 2008; 7: 6: 525-537.
  34. Thijs J., Verhelst H., Van Coster R. Retrospective study of topiramate in a pediatric population with intractable epilepsy showing promising effects in the West syndrome patients. Acta Neurol Belg 2001; 101: 3: 171-176.
  35. Valencia I., Fons C., Kothare S.V. et al. Efficacy and tolerability of topiramate in children younger than 2 years old. J Child Neurol 2005; 20: 8: 667-669.
  36. Veggiotti P., Longaretti F., Signorini S. et al. Topiramate efficacy in an infant with partial seizures refractory to conventional antiepileptic drugs. Seizure 2004; 13: 4: 241-243.
  37. Verdru P. Epilepsy in children: the evidence for new antiepileptic drugs. Acta Neurol Scand 2005; Suppl 181; 17-20.
  38. Wang P., Ren R.N., Cai S.Y. et al. Neuroprotective effects of topiramate and folic acid on young rats with kindling-induced epilepsy. Zhongguo Dang Dai Er Ke Za Zhi 2008; 10: 1: 65-69.
  39. Watemberg N., Goldberg-Stern H., Ben-Zeev B. et al. Clinical experience with open-label topiramate use in infants younger than 2 years of age. J Child Neurol 2003; 18: 4: 258-262.
  40. Wheless J.W. Managing severe epilepsy syndromes of early childhood. Child Neurol 2009; 24: Suppl 8: 24-32.
  41. Wu J.Y., Salamon N., Kirsch H.E. et al. Noninvasive testing, early surgery, and seizure freedom in tuberous sclerosis complex. Neurology 2010; 74: 5: 392-398.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.